Summary of the Conference Call for Zhaoyan New Drug Industry Overview - The conference call focuses on the safety evaluation (安评) industry, particularly the supply and demand dynamics of experimental monkeys, which are crucial for drug development and testing [2][5]. Key Points and Arguments 1. **Strategic Advantage in Monkey Supply**: Zhaoyan possesses its own monkey breeding facilities, which provides a strategic advantage in a market where the supply of experimental monkeys, especially F2 generation monkeys, is limited due to long breeding cycles [2][4]. 2. **Profit Growth and Valuation Potential**: The company has achieved growth in net profit attributable to shareholders through the appreciation of biological assets and increased service fees, indicating significant potential for valuation enhancement as it transitions from preclinical to clinical stages [2][4]. 3. **Industry Leadership**: With 30 years of experience in the safety evaluation industry, Zhaoyan is one of the leading companies in China, holding GLP qualifications from multiple regulatory bodies including NMPA, FDA, and OECD, which allows it to meet global IND approval requirements [2][4]. 4. **High Barriers to Entry**: The safety evaluation industry has high entry barriers due to the substantial costs and long timelines associated with GLP laboratory construction, resulting in a high outsourcing rate. Zhaoyan's qualifications and experience position it favorably in the competitive landscape [2][5]. 5. **Offshore Outsourcing Growth**: The company has leveraged domestic monkey resources and labor to secure high-value offshore orders, achieving a 60% year-on-year growth in offshore outsourcing orders, which is expected to further expand its market share [2][5]. 6. **Supply and Demand Imbalance**: The industry currently faces a mismatch between supply and demand, with a decline in the supply of experimental monkeys due to price differences between China and the U.S., as well as a decrease in birth rates caused by aging populations [6]. 7. **Rising Prices and Service Fees**: The supply-demand imbalance has led to an increase in the price of experimental monkeys, currently exceeding 100,000 yuan per monkey, alongside rising service fees, contributing to an upward trend in the industry's overall prosperity [6]. Future Development Trends 1. **Increased Investment in Innovative Drug Development**: There is a growing investment in innovative drug development driven by factors such as active IPOs in Hong Kong and increased fundraising activities, which is expected to significantly boost demand for safety evaluation services [3][7]. 2. **Continued Tightness in Monkey Resources**: The ongoing tightness in experimental monkey resources is anticipated to persist due to long breeding cycles and low output rates, enhancing Zhaoyan's bargaining power and ability to command premium service fees [3][7]. 3. **Expansion of Offshore Outsourcing Market**: As global resources for experimental monkeys become scarcer, Zhaoyan is well-positioned to further penetrate the offshore outsourcing market, potentially securing higher-margin orders and driving business growth [3][7].

Group 1 - The stock price of Zhaoyan New Drug (603127) reached a new high of 19.49 HKD, surpassing the previous high in March and marking the highest price since September 2023 [1] - The stock experienced significant volatility, with a nearly 30% drop in April due to market turbulence and regulatory changes, followed by a recovery of over 40% in May [1][4] - After peaking on June 17, the stock faced a three-day decline, dropping to a low of 13.89 HKD, a decrease of 28.73% from the peak [1] Group 2 - The Hang Seng Healthcare Index also rebounded after a five-day decline, indicating continued upward momentum in the Hong Kong pharmaceutical sector [2] - Investors are closely watching whether Zhaoyan New Drug can achieve new highs amid ongoing market fluctuations [2] Group 3 - Since the beginning of the year, southbound funds have accumulated a net purchase of nearly 700 billion HKD in Hong Kong stocks, with the healthcare sector showing significant gains [4] - The holding ratio of southbound funds in Zhaoyan New Drug increased from 37.58% to 40.64% in 2025, indicating a trend of increased investment [4][6] - The investment behavior of northbound funds shifted from "buying on dips" to "buying on rises" and back to "buying on dips" again, reflecting changing market dynamics [6] Group 4 - The recent surge in the Hong Kong innovative drug sector is driven by improved performance, policy optimization, and low valuations [4] - The financing environment for the domestic biopharmaceutical sector has improved, with a notable increase in investment cases and amounts in Q1 2025 [7] - The number of clinical approvals for new drugs in China has significantly increased, with 186 first-class new drugs receiving clinical approval in Q1 2025 [8][10] Group 5 - Zhaoyan New Drug reported a 115.11% year-on-year increase in net profit for Q1 2025, indicating strong financial performance despite market fluctuations [10] - The National Medical Products Administration's recent announcement aims to optimize the clinical trial review process, potentially accelerating the approval timeline for innovative drugs [10][12] - The average duration for new drug IND tasks in China is currently 71 days, with plans to reduce this to 30 working days, which could stimulate demand for Zhaoyan New Drug's services [12]